Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: Relationship to rodent liver tumour formation

Xenobiotica

Volumn 39, Issue 8, 2009, Pages 582-596

  Lake, B G ^a,b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b LFI Molecular Sciences   (United Kingdom)

Author keywords

Constitutive androstane receptor; Cytochrome P450; Mode of action; Peroxisome proliferator activated receptor alpha; Peroxisome proliferators; Phenobarbitone; Rodent liver tumours; Species differences

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; BEZAFIBRATE; CHLORPHENOTANE; CINNAMYL ANTHRANILATE; CIPROFIBRATE; CLOFIBRATE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B; CYTOCHROME P450 4A; DI (2 ETHYLHEXYL)ADIPATE; DIELDRIN; DIETHYLNITROSAMINE; ENZYME INDUCING AGENT; FENOFIBRATE; FOMESAFEN; METHYLCLOFENAPATE; METOFLUTHRIN; NAFENOPIN; NITROSOMORPHOLINE; OXAZEPAM; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENOBARBITAL; PHENYTOIN; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; PYRETHRIN; REACTIVE OXYGEN METABOLITE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ALKANE 1 MONOOXYGENASE; HYPNOTIC SEDATIVE AGENT; UNSPECIFIC MONOOXYGENASE;

APOPTOSIS; CANCER RISK; CARCINOGENICITY; CELL PROLIFERATION; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; EXPERIMENTAL MODEL; GENOTOXICITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER HYPERTROPHY; LIVER MICROSOME; LIVER SIZE; LIVER TUMOR; LIVER WEIGHT; MITOGENICITY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; RECEPTOR UPREGULATION; REVIEW; RODENT; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; STEM CELL EXPANSION; ANIMAL; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; HAMSTER; METABOLISM; MOUSE; RAT;

MUS; RATTUS; RODENTIA;

ALKANE 1-MONOOXYGENASE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CRICETINAE; DNA REPLICATION; ENZYME INDUCTION; HUMANS; HYPNOTICS AND SEDATIVES; LIVER NEOPLASMS; MICE; MICROSOMES, LIVER; PHENOBARBITAL; RATS; SPECIES SPECIFICITY;

EID: 70349577386     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903098184     Document Type: Review

References (163)

1. Aiges HW, Daum F, Olson M, Kahn E, Teichberg S. (1980). The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J Pediatr 97:22-26
2. Al Kholaifi A, Amer A, Jeffery B, Gray TJB, Roberts RA, Bell DB. (2008). Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARα. Toxicol Sci 104:74-85.
3. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IFH. (1994) Mechanisticallybased human hazard assessment of peroxisome proliferator- induced hepatocarcinogenesis. Hum Exptl Toxicol 13 (Suppl. 2):S1-S117. (Pubitemid 24356585)
4. Baker TK, Bachowski S, Stevenson DE, Walborg EF Jr, Klaunig JE. (1995). Modulation of gap junctional intercellular communication in rodent, monkey and human hepatocytes by non-genotoxic compounds. Prog Clin Biol Res 391:71-80.
5. Barrass NC, Price RJ, Lake BG, Orton TC. (1993) Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver. Carcinogenesis 14:1451-1456
6. Bars RG, Mitchell AM, Wolf CR, Elcombe CR. (1989). Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry. Biochem J 262:151-158
7. Bell DR, Bars RG, Gibson GG, Elcombe CR. (1991). Localization and differential induction of cytochrome P450IVA and acyl-CoA oxidase in rat liver. Biochem J 275:247-252
8. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand H-J. (1993). Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31:857-907.
9. Bichet N, Cahard D, Fabre G, Remandet B, Gouy D, Cano JP. (1990). Toxicological studies on a benzofuran derivative. III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol Appl Pharmacol 106:509-517
10. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, Farland W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36:781-792 (Pubitemid 44800328)
11. Bursch W, Chabicovsky M, Wastl U, Grasl-Kraupp B, Bukowska K, Taper H, Schulte-Hermann R. (2005b). Apoptosis in early stages of mouse hepatocarcinogenesis: failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility. Toxicol Sci 85:515-529
12. Bursch W, Lauer B, Timmermann-Trosiener I, Barthel G, Schuppler J, Schulte-Hermann R. (1984). Controlling death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 5:453-458
13. Bursch W, Wastl U, Hufnagl K, Schulte-Hermann R. (2005a). No increase in apoptosis in regressing mouse liver after withdrawal of growth stimuli or food restriction. Toxicol Sci 85:507-514
14. Butterworth BE, Smith-Oliver T, Earle L, Loury DJ, White RD, Doolittle DJ, Working PK, Cattley RC, Jirtle R, Michalopoulos G, Strom S. (1989). Use of primary cultures of human hepatocytes in toxicology studies. Cancer Res 49:1075-1084
15. Cariello NF, Romach EH, Colton HM, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT. (2005). Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the Cynomolgus monkey liver. Toxicol Sci 88:250-264
16. Carthew P, Edwards RE, Nolan BM. (1998). The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly in the rat liver by phenobarbital. Toxicol Sci 44:46-51.
17. Carthew P, Maronpot RR, Foley JF, Edwards RE, Nolan BM. (1997). Method for determining whether the number of hepatocytes in rat liver is increased after treatment with the peroxisome proliferator gemfibrozil. J Appl Toxicol 17:47-51.
18. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator- activated receptor-α Cancer Res 64:3849-3854
19. Chiang JY, Steggles AW. (1983). Identification and partial purification of hamster microsomal cytochrome P-450 isoenzymes. Biochem Phamacol 32:1389-1397
20. Chipman JK, Mally A, Edwards GO. (2003). Disruption of gap junctions in toxicity and carcinogenicity. Toxicol Sci 71:146-153
21. Choudhury AI, Chahal S., Bell AR, Tomlinson SR, Roberts RA, Salter AM, Bell DR. (2000). Species differences in peroxisome proliferation: mechanisms and relevance. Mutat Res 448:201-212
22. Choudhury AI, Sims HM, Horley NJ, Roberts RA, Tomlinson SR, Salter AM, Bruce M, Shaw PN, Kendall D, Barrett DA, Bell DR. (2004). Molecular analysis of peroxisome proliferation in the hamster. Toxicol Appl Pharmacol 197:9-18.
23. Cohen SM, Klaunig J, Meek ME, Hill RN, Pastoor T, Lehman- McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, Fenner-Crisp P, Patton D. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci 78:181-186
24. Cohen SM, Meek ME, Klaunig JE, Patton DE, Fenner-Crisp PA. (2003). The human relevance of information on carcinogenic modes of action: overview. Crit Rev Toxicol 33:581-589
25. Corcos L, Berthou F. (2008). The CYP2B subfamily. In: Ioannides C, ed. Cytochromes P450. Role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: RSC. p. 178-199
26. Crunkhorn SE, Plant KE, Gibson GG, Kramer K, Lyon J, Lord PG, Plant NJ. (2004). Gene expression changes in rat liver following exposure to liver growth agents: role of Kupffer cells in xenobioticmediated liver growth. Biochem Phamacol 67:107-118
27. de la Iglesia FA, McGuire EJ, Haskins JR, Lalwani ND. (1996). Structural diversity of peroxisome proliferators and their effects on mammalian liver cells in vivo. Ann NY Acad Sci 804:310-327
28. Dickins M. (2004). Induction of cytochromes P450. Curr Topics Med Chem 4:1745-1766
29. Diwan BA, Henneman JR, Rice JM, Nims RW. (1996). Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5- dichloropyridyloxy)]benzene in rats at doses that cause maximal induction of CYP2B. Carcinogenesis 17:37-43.
30. Diwan BA, Lubet RA, Ward JM, Hrabie JA, Rice JM. (1992). Tumor promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5- dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis 13:1893-1901
31. Diwan BA, Ward JM, Anderson LM, Hagiwara A, Rice JM. (1986). Lack of effect of phenobarbital on hepatocellular carcinogenesis initiated by N-nitrosodiethylamine or methylazoxymethanol acetate in male Syrian golden hamsters. Toxicol Appl Pharmacol 86:298-307.
32. Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J., Wilkinson C, Williams G, van Gemert M. (1999). A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol 29:327-357
33. Durnford JM, Brody RS, Hejtmancik MR, Kurtz PJ, Renne RA, Gideon KM, Marsman DS. (1995). Differential enzyme inducing activity of peroxisome proliferators in the male Syrian hamster. Int Toxicol 7: 47-P-4.
34. Dutton DR, McMillen SK, Parkinson A. (1988). Induction of cytochrome P-450 by phenobarbital and 3-methylcholanthrene: differences between rats and hamsters. Toxicologist 8(1):8.
35. Eacho PI, Foxworthy PS, Johnson WD, Hoover DM, White SL. (1986). Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol Appl Pharmacol 83:430-437
36. Eacho PL, Lanier TL, Brodhecker CA. (1991). Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis 12:1557-1561
37. Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG. (2003). Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282-288
38. Elcombe CR, Bell DR, Elias E, Hasmall SC, Plant NJ. (1996). Peroxisome proliferators: species differences in response of primary hepatocyte cultures. Ann NY Acad Sci 804:628-635
39. Eldridge SR, Tilbury LF, Goldsworthy TL, Butterworth BE. (1990). Measurement of chemically induced cell proliferation in rodent liver and kidney: a comparison of 5-bromo-2́-deoxyuridine and [3H]thymidine administered by injection or osmotic pump. Carcinogenesis 11:2245-2251
40. Fidaleo M. (2009). Human health risk assessment for peroxisome proliferators: more than 30 years of research. Exptl Toxicol Pathol 61:215-221
41. Foster JR. (2000). Cell death and cell proliferation in the control of normal and neoplastic tissue growth. Toxicol Pathol 28:441-446
42. Galloway SM, Johnson TE, Armstrong MJ, Ashby J. (2000). The genetic toxicology of the peroxisome proliferator class of rodent hepatocarcinogen. Mutat Res 448:153-158
43. Garcia-Allan C, Loughlin J, Orton T, Lord P. (1997). Changes in protein and mRNA levels of growth factor/growth factor receptors in rat livers after administration of phenobarbitone and methylclofenapate. Arch Toxicol 71:409-415
44. Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L, Daujat M, Waechter F, Fabre J-M, Carrère N, Maurel P. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251
45. Gibson GG. (1989). Comparative aspects of the mammalian cytochrome P450 IV gene family. Xenobiotica 19:1123-1148
46. Gibson GG. (1993). Peroxisome proliferators: paradigms and prospects. Toxicol Lett 68:193-201.
47. Gibson GG. (1996). Peroxisome proliferators and cytochrome P4504A induction. Ann NY Acad Sci 804:328-340
48. Gibson GG, Orton TC, Tamburini PP. (1982). Cytochrome P-450 induced by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid). Biochem J 203:161-8.
49. Gill JH, James NH, Roberts RA, Dive C. (1998). The non-genotoxic carcinogen nafenopin suppresses rodent hepatocyte apoptosis induced by TGFβ1, DNA damage and Fas. Carcinogenesis 19:299-304.
50. Gold LS, Manley NB, Slone TH, Ward JM. (2001). Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol. Pathol. 29:639-652
51. Goldsworthy TL, Fransson-Steen R. (2002). Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol Pathol 20:97-105.
52. Goll V, Alexandre E, Viollon-Abadie C, Nicod L, Jaeck D, Richert L. (1999). Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxic Appl Pharmacol 160:21-32.
53. Gonzalez FJ, Shah YM. (2008). PPARα: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246:2-8.
54. Gooding PE, Chayen J, Sawyer B, Slater TF. (1978). Cytochrome P-450 distribution in rat liver and the effect of sodium phenobarbitone administration. Chem Biol Interact 20:299-310.
55. Graham MJ, Lake BG. (2008). Induction of drug metabolism: species differences and toxicological relevance. Toxicology 254:184-191
56. Graham MJ, Wilson SA, Winham MA, Spencer AJ, Rees JA, Old SL, Bonner FW. (1994). Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fund Appl Toxicol 22:58-64.
57. Graham RA, Goodwin B, Merrihew RV, Krol WL, LeCluyse EL. (2006). Cloning, tissue expression, and regulation of Beagle dog CYP4A genes. Toxicol Sci 92:356-367
58. Grasso P, Hinton RH. (1991). Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. Mutat Res 248:271-290
59. Griffin RJ, Dudley CN, Cunningham ML. (1996) Biochemical effects of the mouse hepatocarcinogen oxazepam: similarities to phenobarbital. Fund Appl Toxicol 29:147-154
60. Hagiwara A, Miyata E, Tamano S, Sano M, Masuda C, Funae Y, Ito N, Fukushima S, Shirai T. (1999). Non-carcinogenicity, but doserelated increase in preneoplastic hepatocellular lesions, in a two-year feeding study of phenobarbital sodium in male F344 rats. Food Chem Toxicol 37:869-879
61. Hasmall SC, James NH, Macdonald N, Gonzalez FJ, Peters JM, Roberts RA. (2000). Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARα and TNFα Mutat Res 448:193-200.
62. Hasmall SC, James NH, Soames AR, Roberts RA. (1998). The peroxisome proliferator nafenopin does not suppress hepatocyte apoptosis in guinea-pig liver in vivo nor in human hepatocytes in vitro. Arch Toxicol 72:777-783
63. Hasmall SC, Roberts RA. (1999). The perturbation of apoptosis and mitosis by drugs and xenobiotics. Pharmacol Ther 82:63-70.
64. Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. (2005). Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26:219-227
65. Hewitt NJ, LeCluyse EL, Ferguson SS. (2007). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224
66. Hirose Y, Nagahori N, Yamada T, Deguchi Y, Tomigahara Y, Nishioka K, Uwagawa S, Kawamura S, Isobe N, Lake BG, Okuno Y. (2009). Comparison of the effects of the synthetic pyrethroid Metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes. Toxicology 258:64-69
67. Hoivik DJ, Qualls CW Jr, Mirabile RC, Cariello NF, Kimbrough CL, Colton HM, Anderson SP, Santostefano MJ, Ott Morgan RJ, Dahl RR, Brown AR, Zhao Z, Mudd PN Jr, Oliver WB Jr, Brown HR, Miller RT. (2004). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 25:1757-1769
68. Holsapple MP, Pitot HC, Cohen SH, Boobis AR, Klaunig JE, Pastoor T, Dellarco VL, Dragan YP. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci 89:51-56
69. Honkakoski P, Negishi M. (2000). Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347:321-337
70. Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, Moore DD. (2005). Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 19:1646-1653
71. Huff J, Cirvello J, Haseman J, Bucher J. (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ Health Perspect 93:247-270
72. Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. (2003) Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 24:757-770
73. Imaoka S, Osada M, Minamiyama Y, Yukimura T, Toyokuni S, Takemura S, Hiroi T, Funae Y. (2004). Role of phenobarbitalinducible cytochrome P450s as a source of active oxygen species in DNA-oxidation. Cancer Lett 203:117-125
74. International Agency for Research on Cancer (IARC). (2001). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 79. Some thyrotropic agents. Lyon: IARC Press.
75. Ioannides C. (2008). Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: RSC.
76. James NH, Roberts RA. (1994). The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes. Carcinogenesis 15:2687-2694
77. James NH, Roberts RA. (1995). Species differences in the clonal expansion of hepatocytes in response to the coaction of epidermal growth factor and nafenopin, a hepatocarcinogenic peroxisome proliferator. Fundam Appl Toxicol 26:143-149
78. James NH, Roberts RA. (1996). Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 17:1623-1632
79. Jones CR, Lubet RA. (1992). Induction of a pleiotropic response by phenobarbital and related compounds. Response of various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochem Pharmacol 44:1651-1660
80. Jones HB, Orton TC, Lake BG. (2009). Effect of chronic phenobarbitone administration on liver tumour formation in the C57BL/10J mouse. Food Chem Toxicol 47:1333-1340
81. Kamendulis LM, Isenberg JS, Smith JH, Pugh G Jr, Lington AW, Klaunig JE. (2002). Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes. J Toxicol Environ Health 65:569-588
82. Kamendulis LM, Kolaja KL, Stevenson DE, Walborg EF Jr, Klaunig JE. (2001). Comparative effects of dieldrin on hepatic ploidy, cell proliferation, and apoptosis in rodent liver. J Toxicol Environ Health 62:127-141
83. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner- Crisp PA. (2003). PPARa agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33:655-780.
84. Klaunig JE, Ruch RJ, Weghorst CM. (1990). Comparative effects of phenobarbital, DDT, and lindane on mouse hepatocyte gap junctional intercellular communication. Toxicol Appl Pharmacol 102:553-563
85. Kolaja KL, Stevenson DE, Johnson JT, Walborg EF Jr, Klaunig JE. (1996a). Subchronic effects of dieldrin and phenobarbital on hepatic DNA synthesis in mice and rats. Fundam Appl Toxicol 29:219-228
86. Kolaja KL, Stevenson DE, Johnson JT, Walborg EF Jr, Klaunig JE. (1996b). Dose dependence of phenobarbital promotion of preneoplastic hepatic lesions in F344 rats and B6C3F1 mice: effects on DNA synthesis and apoptosis. Carcinogenesis 17:947-954
87. Koufaris C, Wright J, Currie R, Gooderham NJ. (forthcoming 2009). Carcinogenic and non-carcinogenic doses of phenobarbital cause distinct microRNA profiles in male Fischer rats after 14 days of dietary exposure. Poster presentation at the British Toxicology Annual Congress 2009. Toxicology.
88. Kraupp-Grasl B, Huber W, Taper H, Schulte-Hermann R. (1991). Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci. Cancer Res 51:666-671
89. Lake BG. (1995). Mechanisms of hepatocarcinogenicity of peroxisome- proliferating drugs and chemicals. Annu Rev Pharmacol Toxicol 35:483-507.
90. Lake BG, Evans JG, Cunninghame ME, Price RJ. (1993) Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ Health Perspect 101 (Suppl. 5):241-247
91. Lake BG, Evans JG, Gray TJB, Körösi SA, North CJ. (1989). Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig and marmoset. Toxicol Appl Pharmacol 99:148-160
92. Lake BG, Gray TJB, Foster JR, Stubberfield CR, Gangolli SD. (1984b). Comparative studies on di-(2-ethylhexyl)phthalate-induced hepatic peroxisome proliferation in the rat and hamster. Toxicol Appl Pharmacol 72:46-60.
93. Lake BG, Gray TJB, Pels Rijcken WR, Beamand J, Gangolli SD. (1984a). The effect of hypolipidaemic agents on peroxisomal β-oxidation and mixed-function oxidase activities in primary cultures of rat hepatocytes. Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation. Xenobiotica 14:269-276
94. Lake BG, Lewis DFV. (1996). The CYP4 family. In: Ioannnides C, ed. Cytochromes P450: metabolic and toxicological aspects. Boca Raton, FL: CRC Press. p. 271-297
95. Lake BG, Rumsby PC, Cunninghame ME, Price RJ. (2002). Doserelated effects of the peroxisome proliferator methylclofenapate in rat liver. Environ Toxicol Pharmacol 11:233-242
96. Lake BG, Rumsby PC, Price RJ, Cunninghame ME. (2000). Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-β1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res 448:213-225
97. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G. (2001). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferatoractivated receptor (PPAR) α PPARα fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276:31521-31527
98. Lee SS-T, Pineau T, Drago J, Lee EJ, Owens JW., Kroetz DL, Fernandez- Salguero PM, Westphal H, Gonzalez FJ. (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3022
99. Lehman-McKeeman LD, Caudill D, Vassallo JD, Fix AS. (1999). Increased spontaneous liver tumor susceptibility in cytochrome P450 2B1 (CYP2B1) transgenic mice. Toxicol Sci 48 (Suppl. 1):253.
100. Lin JH. (2006). CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116
101. Makowska JM, Gibson GG, Bonner FW. (1992). Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J Biochem Toxicol 7:183-191
102. Marsman DS, Cattley RC, Conway JG, Popp JA. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di-(2-ethylhexyl)phthalate and [4-chloro-6-(2,3- xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 48:6739-6744
103. Martignoni M, Groothuis GMM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894
104. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman- McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33:591-653.
105. Meredith C, Scott MP, Barton A, Price RJ, Hupp TR, Elcombe CR, Lake BG. (2004). Effect of furan, chloroform, di-(2-ethylhexyl) phthalate (DEHP) and oxazepam on biomarkers of cell cycling and proliferation in mouse liver. Toxicol Sci 78 (Suppl. 1):abstract 1716.
106. Moore JT, Moore LB, Maglich JM, Kliewer SA. (2003). Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 1619:235-238
107. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127
108. Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. (2006). Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,463-induced liver tumorigenesis. Carcinogenesis 27:1074-1080
109. Neveu MJ, Babcock KL, Hertzberg EL, Paul DL, Nicholson BJ, Pitot HC. (1994). Colocalized alterations in connexin32 and cytochrome P450IIB1/2 by phenobarbital and related liver tumor promoters. Cancer Res. 54:3145-3152
110. Nims RW, Devor DE, Henneman JR, Lubet RA. (1987). Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates. Carcinogenesis 8:67-71.
111. Nims RW, Lubet RA. (1995). Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. J Toxicol Envionr Health 46:271-292
112. Nims RW, Lubet RA. (1996). The CYP2B subfamily. In: Ioannides C, ed. Cytochromes P450: metabolic and toxicological aspects. Boca Raton, FL: CRC Press. p. 135-160
113. Olsen JH, Boice JD Jr, Jensen JPA, Fraumeni JF Jr. (1989). Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 81:803-808
114. Olsen JH, Schulgen G, Boice JD Jr, Whysner J, Travis LB, Williams GM, Johnson FB, McGee, JO' D. (1995). Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res 55:294-297
115. Orton TC, Adam HK, Bentley M, Holloway B, Tucker MJ. (1984). Clobuzarit: species differences in the morphological and biochemical response of the liver following chronic administration. Toxicol Appl Pharmacol 73:138-151
116. Orton TC, Doughty SE, Kalinowski AE, Lord PG, Wadsworth PF. (1996). Expression of growth factors and growth factor receptors in the liver of C57BL/10J mice following administration of phenobarbitone. Carcinogenesis 17:973-981
117. Osimitz TG, Lake BG. (forthcoming 2009). Mode of action analysis for induction of rat liver tumors by Pyrethrins: relevance to human cancer risk. Crit Rev Toxicol 39(6):501-511
118. Pacot C, Petit M, Rollin M, Behechti N, Moisant M, Deslex P, Althoff J, Lhuguenot JC, Latruffe N. (1996). Differences between guinea pig and rat in the liver peroxisome response to equivalent plasmatic level of ciprofibrate. Arch Biochem Biophys 327:181-188
119. Parke DV. (1968). The biochemistry of foreign compounds. Oxford: Pergamon.
120. Parkinson A. (2001). Biotransformation of xenobiotics. In: Klaassen CD, ed. Casarett and Doull's toxicology: the basic science of poisons. 6th Ed. New York, NY: McGraw Hill. p. 133-224.
121. Parzefall W, Erber E, Sedivy R, Schulte-Hermann R. (1991). Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Res 51:1143-1147
122. Pascussi J-M, Gerbal-Chaloin S, Drocourt L, Assénat E, Larrey D, Pichard-Garcia L, Vilarem M-J, Maurel P. (2004). Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34:633-664
123. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. (1998). Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253 (Pubitemid 29017141)
124. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
125. Perrone CE, Shao L, Williams GM. (1998). Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150:277-286
126. Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ. (1998). Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis 19:1989-1994
127. Peters JM, Cattley RC, Gonzalez FJ. (1997). Role of PPARα in the mechanism of action of the non-genotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18:2029-2033
128. Phillips JC, Price RJ, Cunninghame ME, Osimitz TG, Cockburn A, Gabriel KL, Preiss F, Butler WH, Lake BG. (1997). Effect of piperonyl butoxide on cell replication and xenobiotic metabolism in the livers of CD-1 mice and F344 rats. Fundam Appl Toxicol 38:64-74.
129. Pirttiaho HI, Sotaniemi E.A, Ahokas JT, Pitkänen U. (1978). Liver size and indices of drug metabolism in epileptics. Br J Clin Pharmacol 6:273-278
130. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U. (1982). Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 22:441-445
131. Plant NJ, Horley NJ, Dickins M, Hasmall S, Elcombe CR, Bell DR. (1998). The coordinate regulation of DNA synthesis and suppression of apoptosis is differentially regulated by the liver growth agents, phenobarbital and methylclofenapate. Carcinogenesis 19:1521-1527
132. Price RJ, Evans JG, Lake BG. (1992) Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian hamster. Food Chem Toxicol 30:937-944
133. Pustylnyak VO, Lebedev AN, Gulyaeva LF, Lyakhovich VV, Slynko NM. (2007). Comparative study of CYP2B induction in the liver of rats and mice by different compounds. Life Sci 80:324-328
134. Raucy JL, Lasker J, Ozaki K, Zoleta V. (2004). Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci 79:233-241
135. Reddy JK, Lalwani ND. (1983). Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12:1-58.
136. Rice JM, Diwan BA, Hu H, Ward JM, Nims RW, Lubet RA. (1994). Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. Carcinogenesis 15:395-402.
137. Richert L, Lamboley C, Viollon-Abadie C, Grass P, Hartmann N, Laurent S, Heyd B, Mantion G, Chibout S-D, Staedtler F. (2003). Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol 191:130-146
138. Richert L, Price S, Chesne C, Maita K, Carmichael N. (1996). Comparison of the induction of hepatic peroxisome proliferation by herbicide oxadiazon in vivo in rats, mice, and dogs and in vitro in rat and human hepatocytes. Toxicol Appl Pharmacol 141:35-43.
139. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. (2007). Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 96:2-15.
140. Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB. (1995). Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis 16:1693-1698
141. Roglans N, Bellido A, Rodriguez C, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC. (2002). Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver. Clin Pharmacol Ther 72:692-701.
142. Ross PK, Woods CG, Bradford BU, Kosyk O, Gatti DM, Cunningham ML, Rusyn I. (2009). Time-course comparison of xenobiotic activators of CAR and PPARα in mouse liver. Toxicol Appl Pharmacol 235:199-207.
143. Schulte-Hermann R, Kraupp-Grasl B, Bursch W, Gerbracht U, Timmermann-Trosiener I. (1989). Effects of non-genotoxic hepatocarcinogens phenobarbital and nafenopin on phenotype and growth of different populations of altered foci in rat liver. Toxicol Pathol 17:642-649
144. Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, Bursch W. (1990). DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 50:5127-5135 (Pubitemid 20257947)
145. Schulte-Hermann R, Timmermann-Trosiener I, Schuppler J. (1983). Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res 43:839-844
146. Schulte-Hermann R, Timmermann-Trosiener I, Schuppler J. (1986). Facilitated expression of adaptive responses to phenobarbital in putative pre-stages of liver cancer. Carcinogenesis 7:1651-1655
147. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez F.J. (2007). Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27:4238-4247
148. Sharma R, Lake BG, Foster J, Gibson GG. (1988). Microsomal cytochrome P-452 induction and peroxisome proliferation by hypolipidaemic agents in rat liver. A mechanistic inter-relationship. Biochem Pharmacol 37:1193-1201
149. Stenbäck F, Mori H, Furuya K, Williams GM. (1986). Pathogenesis of dimethylnitrosamine-induced hepatocellular cancer in hamster liver and lack of enhancement by phenobarbital. J Natl Cancer Inst 76:327-333
150. Styles JA, Kelly M, Pritchard NR, Elcombe CR. (1988). A species
151. Tanaka T, Mori H, Williams GM. (1987). Enhancement of dimethylnitrosamine- initiated hepatocarcinogenesis in hamsters by subsequent administration of carbon tetrachloride but not by phenobarbital or p,ṕ-dichlorodiphenyltrichoroethane. Carcinogenesis 8:1171-1178
152. Thorpe E, Walker AIT. (1973). The toxicology of dieldrin (HEOD). II. Comparative long-term oral toxicity studies in mice with dieldrin, DDT, phenobarbitone, β-BHC and γ-BHC. Food Chem Toxicol 11:433-442
153. Tien ES, Negishi M. (2006). Nuclear receptors CAR and PXR in the regulation of hepatic metabolism. Xenobiotica 36:1152-1163
154. Tucker MJ, Orton TC. (1995). Comparative toxicology of hypolipidaemic fibrates. London: Taylor & Francis.
155. Wada N, Marsman DS, Popp JA. (1992). Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication. Fund Appl Toxicol 18:149-154
156. Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, LeCluyse EL. (2003). Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31:620-630
157. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. (2000). The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407:920-923
158. Whysner J, Ross PM, Williams GM. (1996). Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 71:153-191 (Pubitemid 26323295)
159. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JG, Roberts RA. (1999). The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20:369-372
160. Yamada T, Uwagawa S, Okuno Y, Cohen SM, Kaneko H. (2009). Case study: an evaluation of the human relevance of the synthetic pyrethroid metofluthrin-induced liver tumors in rats based on mode of action. Toxicol Sci 108:59-68.
161. Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, Maronpot RR. (2004). The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 64:7197-7200
162. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. (2008). The PPARα-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARα Toxicol Sci 101:132-139
163. Yoshinari K, Tien E, Negishi M, Honkakoski P. (2008). Receptormediated regulation of cytochromes P450. In: Ioannides C, ed. Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: RSC. p. 417-448